Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R. Mirza, Ursula A. Matulonis, Noa Ben-Baruch et al.|New England Journal of Medicine|2016Cited by 2.5k
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Keiichi Fujiwara et al.|The Lancet Oncology|2021Cited by 401
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Dominique Berton et al.|JAMA Network Open|2023Cited by 120
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Anna V. Tinker, Bhavana Pothuri et al.|Clinical Cancer Research|2023Cited by 80
Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian CarcinomaLindsay DeVorkin, Julian J. Lum, Matthew Hattersley et al.|Molecular Cancer Research|2017Cited by 60